Cardiovascular Medicine Book



Aka: Mibefradil, T-Type Calcium Channel Blocker
  1. See Also
    1. Calcium Channel Blocker
    2. Calcium Channel Blocker Overdose
    3. Dihydropyridine Calcium Channel Blocker (e.g. Amlodipine, Nifedipine)
    4. Diltiazem
    5. Verapamil
  2. Indications
    1. Chronic Stable Angina
    2. Hypertension
  3. Mechanism
    1. Blocks Calcium influx at 2 types of Calcium channels
      1. L-type (long-acting) channels
        1. Blocked by standard Calcium Channel Blockers
      2. T-type (transient) channels
        1. Blocked uniquely by Mibefradil
        2. Activated at lower voltages
        3. Present in:
          1. Vascular Smooth Muscle
          2. Myocardial conduction system
        4. Absent in
          1. Ventricular Myocardium
    2. Effect of Mibefradil
      1. Produces coronary and peripheral vasodilatation
      2. Does not result in reflex Tachycardia
  4. Efficacy
    1. Antihypertensive
      1. More effective then Diltiazem
      2. As effective as Amlodipine and Nifedipine
      3. Synergistic effect with ACE Inhibitors
    2. Anti-Anginal
      1. Delays onset of ischemia during Exercise
      2. Increases Exercise tolerance
  5. Contraindications
    1. Sick Sinus Syndrome
    2. AV Block without a Pacemaker
  6. Drug Interactions
    1. Fatal Arrhythmia risk with
      1. Terfenadine
      2. Astemizole
      3. Cisapride
    2. Increases levels of
      1. Tricyclic Antidepressant
      2. Cyclosporine
  7. Adverse Effects
    1. See Calcium Channel Blocker
    2. Dizziness
    3. Fatigue
    4. Light headedness
    5. Peripheral Edema LESS common than others in class
  8. Dosing
    1. 50 mg orally daily (up to 100 mg orally daily)
  9. References
    1. (1997) Med Lett Drugs Ther 39:103-5 [PubMed]

Mibefradil (C0286185)

Definition (MSH) A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D020748
SnomedCT 421651006, 319318006
English mibefradil, Mibefradil (substance), MIBEFRADIL, Mibefradil, Mibefradil [Chemical/Ingredient], (1S,2S)-(2-((3-(2-Benzimidazolyl)Propyl)Methylamino)Ethyl)-6-Fluoro-1,2,3,4-Tetrahydro-1-Isopropyl-2-Naphthyl Methoxyacetate, Acetic acid, methoxy-, 2-(2-((3-(1H-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, (1S-cis)-, Mibefradil (product)
Spanish mibefradil (sustancia), mibefradil (producto), mibefradil, Mibefradil
Swedish Mibefradil
Czech mibefradil
Finnish Mibefradiili
Japanese ミベフラジル
Polish Mibefradyl
French Mibéfradil
German Mibefradil
Italian Mibefradile
Portuguese Mibefradil
Derived from the NIH UMLS (Unified Medical Language System)

You are currently viewing the original '\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree